AOL Money & Finance

Analyst upgrades, downgrades and initiations: BJ, CX, MRK, VLKAY, WMT ...

More

Analyst upgrades:

  • Deutsche Bank upgraded Cemex (NYSE: CX) to Buy from Hold on decreased dilution risk following the company's successful refinancing and raised its target on shares to $15 from $11.20.
  • Rochdale upgraded Wal-Mart (NYSE: WMT) to Buy from Neutral and raised its target to $65. The firm is positive on Wal-Mart's defensive characteristics, cyclical upside, and competitive position.
  • JPMorgan upgraded Gartner Group (NYSE: IT) to Overweight from Neutral to reflect stabilization in IT industry spending and the stock's attractive valuation. The firm has a $23 price target on the stock.
  • Cavium Networks (NASDAQ: CAVM) was upgraded to Overweight from Equal Weight at Barclays.
  • Borg-Warner (NYSE: BWA) was upgraded to Buy from Neutral at BofA/Merrill.
  • Nanometrics (NASDAQ: NANO) was upgraded to Outperform from Perform at Oppenheimer.

Analyst downgrades:

  • JPMorgan downgraded BJ's Wholesale (NYSE: BJ) to Neutral from Overweight. The firm believes food disinflation poses risk to the company's second half of 2009 SSS outlook and has a $34 target on the stock.
  • Wells Fargo downgraded Public Storage (NYSE: PSA) to Market Perform from Outperform. The firm downgraded the stock on valuation, and because it expects same-store NOI growth to remain soft into 2010.
  • Oppenheimer downgraded REIT shares citing the recent strength in the group. BioMed Realty Trust (NYSE: BMR) and Boston Properties (NYSE: BXP) were cut to Outperform from Perform, while Washington REIT (NYSE: WRE) was lowered to Underperform from Perform.
  • Volkswagen (OTC: VLKAY) was downgraded to Neutral from Overweight at HSBC.
  • Boardwalk Pipeline (NYSE: BWP) was downgraded to Hold from Buy at Deutsche Bank.

Analyst initiations:

  • Deutsche Bank initiated STEC (NASDAQ: STEC) with a Buy rating and $45 target. The firm believes the enterprise storage SSD market can grow significantly over the next couple of years and that STEC is attractively valued at current levels.
  • Oppenheimer expects Ariad's (NASDAQ: ARIA) lead cancer drug, Ridaforolimus, will receive approval for sarcoma and estimates peak sales at $350M. Shares were started with an Outperform rating and $4 target.
  • Oppenheimer also initiated American Physicians (NASDAQ: AMPH) with an Outperform rating. The firm believes that the company is poised to deliver attractive returns, since its book value increased by more than 10% last year.
  • Merck (NYSE: MRK) was reinstated with a Buy rating and $34 target at BofA/Merrill.
  • EnerNOC (NASDAQ: ENOC) was initiated with an Overweight rating and $32.50 target at JPMorgan.
  • DigitalGlobe (NYSE: DGI) was initiated with an Overweight rating and $25 target at Morgan Stanley
Symbol Lookup
IndexesChangePrice
DJIA-14.2810,318.16
NASDAQ-10.782,146.04
S&P 500-3.521,091.38

Last updated: November 22, 2009: 11:56 AM

BloggingStocks Exclusives

Hot Stocks

DailyFinance Headlines

Latest from BloggingBuyouts

TheFlyOnTheWall.com Headlines

    BioHealth Investor Headlines

    WalletPop Headlines

    My Portfolios

    Track your stocks here!

    Find out why more people track their portfolios on AOL Money & Finance then anywhere else.

    BloggingStocks Partners

    More from AOL Money & Finance

    WalletPop Headlines